USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation

ChangeBridge: Patent Apps - Pharma (A61K)

Published November 28th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083754A1) filed on November 28, 2025, for novel orally disintegrating tablet compositions containing topically acting corticosteroids. The invention is aimed at treating gastrointestinal inflammation, with a specific focus on eosinophilic esophagitis, by utilizing corticosteroids adsorbed onto carriers like silicified microcrystalline cellulose.

As this is a patent application, it does not impose immediate compliance obligations or deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for GI inflammation. Companies in the pharmaceutical sector, particularly those involved in drug development for inflammatory conditions, should be aware of this patent filing as it may impact their intellectual property landscape and future product development strategies.

Source document (simplified)

← USPTO Patent Applications

CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS

Application US20260083754A1 Kind: A1 Mar 26, 2026

Inventors

Michael A. GOSSELIN, Jin-Wang LAI, Gopi M. VENKATESH

Abstract

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.